loading
전일 마감가:
$38.41
열려 있는:
$38.11
하루 거래량:
703.57K
Relative Volume:
0.48
시가총액:
$291.38M
수익:
-
순이익/손실:
$-121.02M
주가수익비율:
-3.6101
EPS:
-11.26
순현금흐름:
$-114.09M
1주 성능:
+2.19%
1개월 성능:
+115.31%
6개월 성능:
+121.53%
1년 성능:
-88.32%
1일 변동 폭
Value
$38.06
$41.77
1주일 범위
Value
$36.77
$44.30
52주 변동 폭
Value
$7.31
$363.20

토닉스 파마슈티컬스 홀딩 Stock (TNXP) Company Profile

Name
명칭
Tonix Pharmaceuticals Holding Corp
Name
전화
212-980-9155
Name
주소
26 MAIN STREET, SUITE 101, CHATHAM, NY
Name
직원
81
Name
트위터
@TONIXPharma
Name
다음 수익 날짜
2025-03-17
Name
최신 SEC 제출 서류
Name
TNXP's Discussions on Twitter

TNXP을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
TNXP
Tonix Pharmaceuticals Holding Corp
40.65 291.38M 0 -121.02M -114.09M -11.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

토닉스 파마슈티컬스 홀딩 Stock (TNXP) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2022-04-18 개시 Noble Capital Markets Outperform
2019-04-18 업그레이드 ROTH Capital Neutral → Buy
2017-08-18 업그레이드 ROTH Capital Neutral → Buy
2016-09-07 다운그레이드 ROTH Capital Buy → Neutral
2016-02-17 재확인 Oppenheimer Outperform
2015-11-04 개시 Cantor Fitzgerald Buy
2015-06-12 개시 Oppenheimer Outperform
2015-02-17 재확인 ROTH Capital Buy
2014-09-29 재확인 ROTH Capital Buy
모두보기

토닉스 파마슈티컬스 홀딩 주식(TNXP)의 최신 뉴스

pulisher
Jun 06, 2025

Tonix Pharmaceuticals to Showcase Rheumatologic Research at EULAR 2025 - citybuzz -

Jun 06, 2025
pulisher
Jun 05, 2025

Tonix Pharmaceuticals Announces Poster Presentation at the Annua - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025 | TNXP Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Tonix Pharmaceuticals Announces Poster Presentation at the - GlobeNewswire

Jun 05, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Acquires New Shares in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Tonix Pharmaceuticals (TNXP) Price Target Raised to $65 by Alliance Global Partners | TNXP Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 01, 2025

Wall Street Zen Downgrades Tonix Pharmaceuticals (NASDAQ:TNXP) to Sell - Defense World

Jun 01, 2025
pulisher
May 30, 2025

Tonix Pharmaceuticals: August PDUFA Date For Fibromyalgia Med A Risky Bet (NASDAQ:TNXP) - Seeking Alpha

May 30, 2025
pulisher
May 29, 2025

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights - mx.advfn.com

May 29, 2025
pulisher
May 29, 2025

How the (TNXP) price action is used to our Advantage - news.stocktradersdaily.com

May 29, 2025
pulisher
May 29, 2025

Tonix Pharmaceuticals (TNXP) Stock Surges Over 10%: What's Fueling the Rally and What's Next? - Daily Chhattisgarh News

May 29, 2025
pulisher
May 28, 2025

What's Going On With Tonix Pharmaceuticals Stock? - Benzinga

May 28, 2025
pulisher
May 28, 2025

TNXP: Preparations Continue for Potential Commercial Launch of TNX-102 SL in Fibromyalgia… - Yahoo Finance

May 28, 2025
pulisher
May 23, 2025

Tonix Pharmaceuticals CEO Highlights Strategic Vision at Healthcare Showcase - citybuzz -

May 23, 2025
pulisher
May 22, 2025

Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase - GlobeNewswire

May 22, 2025
pulisher
May 21, 2025

Tonix begins trial for stress reaction treatment By Investing.com - Investing.com South Africa

May 21, 2025
pulisher
May 21, 2025

Tonix begins trial for stress reaction treatment - Investing.com Australia

May 21, 2025
pulisher
May 21, 2025

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 O - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Tonix Pharmaceuticals (TNXP) Commences Phase 2 Trial for Stress Disorder Treatment | TNXP Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Tonix Pharmaceuticals Announces First Patient Dosed In Phase 2 Oasis Study Of TNX-102 SL For Reduction Of Acute Stress Reaction - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Tonix Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

DoD Backs Revolutionary Acute Stress Treatment: First Patient Dosed in $3M Phase 2 Trial - Stock Titan

May 21, 2025
pulisher
May 16, 2025

Tonix Pharmaceuticals (TNXP) Stock Surges Following Insider Buying And Q1 Results - Benzinga

May 16, 2025
pulisher
May 15, 2025

Stocks To Watch: Tonix Pharmaceuticals Sees RS Rating Jump To 89 - inkl

May 15, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals Recruits Seasoned Industry Atty As GC - Law360

May 14, 2025
pulisher
May 14, 2025

Tonix Pharma Stock Soars After Roping In Former Celgene Corp Executive Joseph Hand: Retail Gets More Positive - Investing.com India

May 14, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals Names Joseph Hand as General Counsel and Executive Vice President of Operations - citybuzz -

May 14, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals Appoints Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations - citybiz

May 14, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals (TNXP) Appoints New General Counsel and EV - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals (TNXP) Appoints New General Counsel and EVP of Operations | TNXP Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Tonix Pharma Appoints New General Counsel and EVP - TipRanks

May 14, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals Announces Appointment of Joseph Hand, - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Former Celgene $74B Deal Leader Joins Tonix as EVP Before Critical Fibromyalgia Drug Decision - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Resul - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Tonix Pharmaceuticals Q1 2025 Earnings: EPS Loss of $2.84 Beats - GuruFocus

May 13, 2025
pulisher
May 12, 2025

Tonix Pharmaceuticals Holding Corp reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

Tonix Pharma earnings beat by $22.84, revenue fell short of estimates - Investing.com

May 12, 2025
pulisher
May 09, 2025

Tonix Pharmaceuticals reports annual meeting results By Investing.com - Investing.com Nigeria

May 09, 2025
pulisher
May 09, 2025

Tonix Pharmaceuticals reports annual meeting results - Investing.com Australia

May 09, 2025
pulisher
May 08, 2025

Tonix showcases promising gastric cancer data at AACR Conference - Proactive financial news

May 08, 2025
pulisher
May 08, 2025

(TNXP) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 08, 2025
pulisher
May 07, 2025

Tonix Pharma drops after Q4 revenue miss - MSN

May 07, 2025
pulisher
May 06, 2025

Tonix Pharmaceuticals: Looking Past FDA Approval To Challenging Commercial Opportunity - Seeking Alpha

May 06, 2025
pulisher
Apr 29, 2025

Tonix Pharmaceuticals Reveals Promising Preclinical Data for Cancer Immunotherapy TNX-1700 - citybuzz -

Apr 29, 2025
pulisher
Apr 29, 2025

Tonix Pharma Unveils Promising Cancer Treatment Data - TipRanks

Apr 29, 2025
pulisher
Apr 29, 2025

Tonix Pharmaceuticals Presented Preclinical Data on Gastric - GlobeNewswire

Apr 29, 2025
pulisher
Apr 29, 2025

Tonix Pharmaceuticals (TNXP) Showcases Promising Cancer Research at AACR 2025 | TNXP Stock News - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Canc - GuruFocus

Apr 29, 2025

토닉스 파마슈티컬스 홀딩 (TNXP) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
자본화:     |  볼륨(24시간):